Cook Medical Launches Advance 18 PTX Drug-Eluting Balloon in Europe
January 25, 2012—Cook Medical (Bloomington, IN) announced the European launch of its first drug-eluting balloon approved to treat stenotic or occlusive disease in the peripheral vascular system. The Advance 18 PTX received CE Mark approval in December 2011. It is not available for sale in the United States, the company advised.
According to Cook, the Advance 18 PTX combines the mechanical therapy of its Advance balloon with the antiproliferative effects of paclitaxel. The company noted that in its manufacturing process, no polymers or excipients are used, and the balloon is coated before being folded, allowing for more drug-to-vessel contact.
“For the most effective treatment of PAD, physicians worldwide are looking to combination-therapy devices,” commented Prof. Dierk Scheinert, MD. “This new balloon from Cook, combining mechanical intervention with a drug, is an excellent percutaneous transluminal angioplasty treatment option as we continue to embrace new therapies to offer our patients.”